Anti-tuberculosis immunity induced in mice by vaccination with Mycobacterium smegmatis over-expressing Antigen 85B is due to the increased influx of IFNγ-positive CD4 T cells into the lungs

Abstract

SUMMARYBCG vaccine is unsafe for use in patients with AIDS. Mycobacterium smegmatis (Msm), an avirulent species unlike virulent Mycobacterium tuberculosis (H37Rv, Mtb) has been used as a carrier vaccine with ambiguous results due to the elicitation of poor immune responses to antigens in mice. In this study, we over-expressed the immunodominant antigen 85B in M. smegmatis (Msm-OEAg85B) and compared the immunogenicity of Msm-OEAg85B with that of wild-type Msm. Mice which were vaccinated with either Msm or Msm-OEAg85B and challenged 2 weeks later with Mtb. Vaccineinduced protection and lung T cell responses were evaluated post vaccination and post challenge. Unlike wild-type Msm that elicited minimal T cell responses in mice, MsmOE-Ag85B induced enhanced CD4+IFNγ+ T cell responses that leveled off over 2 weeks. After virulent challenge at 2 weeks, Mtb grew progressively in the lungs of naive mice and mice vaccinated with wild-type Msm, but showed reduced growth (<0.6 log 10 ) and therefore protection in Msm-OEAg85B-vaccinated mice. Lungs of Msm-OEAg85B-vaccinated mice showed increased numbers of CD4+IFNγ+ T cells suggesting that the reduced bacterial growth was likely due to the enhanced T cell response in lungs. Since wild-type Msm was unable to protect but Msm-OEAg85B was, we suggest that Msm can be genetically manipulated to over-express selected Mtb antigens, thereby paving the way for safer vaccines that can be used in immunodeficient patients.

Mycobacterium smegmatis, a Promising Vaccine Vector for Preventing TB and Other Diseases: Vaccinomics Insights and Applications

“…After successfully constructing the recombinant strain, they compared its immunogenicity with that of the wild type. The results confirmed that the recombinant strain could effectively stimulate and increase the number of CD4+ IFN-γ + T cells in the lung [63].…”

Protective and Therapeutic Efficacy of Mycobacterium smegmatis Expressing HBHA-hIL12 Fusion Protein against Mycobacterium tuberculosis in Mice

“…Mycobacterium smegmatis is an attenuated species of Mycobacterium that has been previously used as a carrier of vaccine antigens against tuberculosis with ambiguous results [19] . However, it has shown promise as an effective vaccine vector to deliver cytokines that can skew Th1 immunity in mice [16] .…”

Magnetic nanosensors for highly sensitive and selective detection of bacillus Calmette-Guérin

“…The target of our monoclonal antibody was M. tuberculosis Ag85B, which is a powerful antigen shared by M. tuberculosis and the BCG vaccine that induces both T cell and antibody responses in animal models and humans. 30 The presence of free carboxylic acid groups on the surface of CAMNPs facilitates conjugation with amine-containing proteins by crosslinkers (EDC and sulfo-NHS) which activated the carboxylic acid groups and led to the formation of amide bonds with the antibodies. After removing the free antibodies by centrifugation, we quantified the number of antibodies per CAMNP, which was $3 as determined by the bicinchoninic acid (BCA) protein assay kit.…”